Nina Sienna Bozinov, MD | |
700 W Ironwood Dr Ste 158, Coeur D Alene, ID 83814-4404 | |
(208) 625-5100 | |
(208) 625-5101 |
Full Name | Nina Sienna Bozinov |
---|---|
Gender | Female |
Speciality | Neurology |
Experience | 10 Years |
Location | 700 W Ironwood Dr Ste 158, Coeur D Alene, Idaho |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1508286188 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2084N0400X | Psychiatry & Neurology - Neurology | M15262 (Idaho) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Kootenai Health | Coeur d'alene, ID | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Kootenai Health Inc | 1355792276 | 291 |
Kootenai Health, Inc. | 4789641598 | 331 |
News Archive
One of the main obstacles to finding effective therapies for human diseases has been our limited understanding of disease pathogenesis: we lack detailed knowledge of the cellular and molecular mechanisms that lead to the development of disease.
Argos Therapeutics today announced the presentation of positive interim data from a Phase 2 trial that evaluated the clinical activity, safety and immune response of AGS-003 treatment, given in combination with sunitinib, in patients with newly diagnosed advanced renal cell carcinoma (RCC). The data were discussed June 7 in a poster session at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.
Researchers from the University of Granada and the "San Cecilio de Granada" Teaching Hospital confirm that endocrine disruptors—chemical substances that may mimic or block the action of hormones—are present in some cosmetic products
Participating in certain mental activities, like reading magazines or crafting in middle age or later in life, may delay or prevent memory loss, according to a study released today that will be presented at the American Academy of Neurology's 61st Annual Meeting in Seattle, April 25 to May 2, 2009.
› Verified 2 days ago
Entity Name | Kootenai Health, Inc. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1235288655 PECOS PAC ID: 4789641598 Enrollment ID: O20041214000230 |
News Archive
One of the main obstacles to finding effective therapies for human diseases has been our limited understanding of disease pathogenesis: we lack detailed knowledge of the cellular and molecular mechanisms that lead to the development of disease.
Argos Therapeutics today announced the presentation of positive interim data from a Phase 2 trial that evaluated the clinical activity, safety and immune response of AGS-003 treatment, given in combination with sunitinib, in patients with newly diagnosed advanced renal cell carcinoma (RCC). The data were discussed June 7 in a poster session at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.
Researchers from the University of Granada and the "San Cecilio de Granada" Teaching Hospital confirm that endocrine disruptors—chemical substances that may mimic or block the action of hormones—are present in some cosmetic products
Participating in certain mental activities, like reading magazines or crafting in middle age or later in life, may delay or prevent memory loss, according to a study released today that will be presented at the American Academy of Neurology's 61st Annual Meeting in Seattle, April 25 to May 2, 2009.
› Verified 2 days ago
Entity Name | Kootenai Health Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1174661151 PECOS PAC ID: 1355792276 Enrollment ID: O20240111003252 |
News Archive
One of the main obstacles to finding effective therapies for human diseases has been our limited understanding of disease pathogenesis: we lack detailed knowledge of the cellular and molecular mechanisms that lead to the development of disease.
Argos Therapeutics today announced the presentation of positive interim data from a Phase 2 trial that evaluated the clinical activity, safety and immune response of AGS-003 treatment, given in combination with sunitinib, in patients with newly diagnosed advanced renal cell carcinoma (RCC). The data were discussed June 7 in a poster session at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.
Researchers from the University of Granada and the "San Cecilio de Granada" Teaching Hospital confirm that endocrine disruptors—chemical substances that may mimic or block the action of hormones—are present in some cosmetic products
Participating in certain mental activities, like reading magazines or crafting in middle age or later in life, may delay or prevent memory loss, according to a study released today that will be presented at the American Academy of Neurology's 61st Annual Meeting in Seattle, April 25 to May 2, 2009.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Nina Sienna Bozinov, MD 2003 Kootenai Health Way, Coeur D Alene, ID 83814-6051 Ph: (208) 625-5000 | Nina Sienna Bozinov, MD 700 W Ironwood Dr Ste 158, Coeur D Alene, ID 83814-4404 Ph: (208) 625-5100 |
News Archive
One of the main obstacles to finding effective therapies for human diseases has been our limited understanding of disease pathogenesis: we lack detailed knowledge of the cellular and molecular mechanisms that lead to the development of disease.
Argos Therapeutics today announced the presentation of positive interim data from a Phase 2 trial that evaluated the clinical activity, safety and immune response of AGS-003 treatment, given in combination with sunitinib, in patients with newly diagnosed advanced renal cell carcinoma (RCC). The data were discussed June 7 in a poster session at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.
Researchers from the University of Granada and the "San Cecilio de Granada" Teaching Hospital confirm that endocrine disruptors—chemical substances that may mimic or block the action of hormones—are present in some cosmetic products
Participating in certain mental activities, like reading magazines or crafting in middle age or later in life, may delay or prevent memory loss, according to a study released today that will be presented at the American Academy of Neurology's 61st Annual Meeting in Seattle, April 25 to May 2, 2009.
› Verified 2 days ago
Dr. Christin J Mcintyre, MD, PHD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1250 W Ironwood Dr Ste 303, Coeur D Alene, ID 83814 Phone: 503-276-1295 Fax: 234-444-5496 | |
John Michael Thurston, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 250 Northwest Blvd Ste 200, Coeur D Alene, ID 83814 Phone: 208-225-8642 Fax: 208-795-8079 | |
Dr. James Y. Lea, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2022 N Government Way, Coeur D Alene, ID 83814 Phone: 208-667-5536 Fax: 208-765-1194 | |
Dr. Charles William Britt Jr., MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2003 Kootenai Health Way, Coeur D Alene, ID 83814 Phone: 208-625-4000 | |
Dr. Michah Brasseur, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2003 Kootenai Health Way, Coeur D Alene, ID 83814 Phone: 208-625-4000 Fax: 208-625-5101 | |
Lizl Maureen Lasky, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 700 W Ironwood Dr Ste 158, Coeur D Alene, ID 83814 Phone: 208-625-5100 Fax: 208-625-5101 | |
Cynthia Murphy, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 700 W Ironwood Dr Ste 158, Coeur D Alene, ID 83814 Phone: 208-625-5100 Fax: 208-625-5101 |